16:34 EDT ProMIS Neurosciences (PMN) files to sell 28.23M common shares for holders
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN:
- Promising Outlook for ProMIS Neurosciences’ PMN310 in Alzheimer’s Treatment with Buy Rating and $3.00 Price Target
- ProMIS Neurosciences Advances Alzheimer’s Trial to Final Phase
- ProMIS receives DSMB approval to advance final dose escalation cohort
- ProMIS Neurosciences Announces At The Market Offering
- ProMIS Neurosciences: Advancements in Alzheimer’s Treatment and Strong Financial Positioning Drive Buy Rating